Chandigarh, January 1, 2026 – Nectar Lifesciences Limited (NECLIFE) recorded a muted response on the first day of its ongoing share buyback, with the offer subscribed 0.16 times as of 4:00 p.m. on December 31, 2025, largely driven by participation from individual investors.
The company is conducting a fixed-price buyback of up to 3 crore equity shares at ₹27 per share, with the offer window open from December 31, 2025 to January 6, 2026.
Buyback Snapshot
| Particulars | Details |
|---|---|
| Company | Nectar Lifesciences Limited |
| Symbol | NECLIFE |
| Series | BB |
| Offer Type | Buyback |
| Issue Type | Fixed Price |
| Offer Price | ₹27 per equity share |
| Face Value | ₹1 |
| Issue Size | Up to 3,00,00,000 equity shares |
| Offer Period | December 31, 2025 – January 6, 2026 |
| Market Lot | 1 equity share |
| Market Timings | 9:15 a.m. to 3:30 p.m. |
Subscription Status (As on December 31, 2025 | 4:00 p.m.)
| Category | Shares Bid |
|---|---|
| Qualified Institutional Buyers (QIBs) | 9,000 |
| Non-Institutional Investors | 51,000 |
| Individual Investors | 48,56,947 |
| Total | 49,16,947 |
Category-wise Participation
Individual Investors Lead the Book
Retail investors accounted for the bulk of the demand, bidding for 48.57 lakh shares, reflecting continued interest from smaller shareholders in the tender offer.Institutional Interest Remains Limited
Participation from the institutional segment remained negligible, with QIB bids restricted to 9,000 shares, while mutual funds, insurance companies, and foreign institutions did not place bids on Day One.Price-wise Order Data
| Price (₹) | No. of Orders | Demat Quantity | Physical Quantity | Total Quantity |
|---|---|---|---|---|
| 27.00 | 1,060 | 49,16,947 | – | 49,16,947 |
Offer Management Details
| Particulars | Information |
|---|---|
| Acquirer | Nectar Lifesciences Limited |
| Book Running Lead Manager | Master Capital Services Limited |
| Registrar | KFin Technologies Limited |
| Registrar Address | Selenium, Tower B, Plot Nos. 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally Mandal, Hyderabad – 500032 |
| Contact | M. Murali Krishna |
| Phone | +91 40 6716 2222 / 18003094001 |
| nectar.buyback@kfintech.com |
About the Company
Nectar Lifesciences Limited is a listed entity on Indian stock exchanges and has historically operated in the pharmaceutical sector. Following major business divestments completed during 2025, the company is currently evaluating new strategic opportunities. The ongoing buyback is aimed at returning surplus capital to shareholders and optimising the company’s equity structure.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.